Child with relapsing steroid sensitive nephrotic syndrome (≥2 relapses in preceding 12 months)

Randomised (post-recruitment)

Active treatment arm

Prednisolone administered daily for 6 days commenced within 24 hours of onset of first URTI

Prednisolone administered daily for 6 days commenced within 24 hours of onset of each subsequent URTI over 12 month follow-up period

Control arm

No change to current prednisolone at time of first URTI with use of placebo tablets to blind study

No change to current prednisolone at time of each subsequent URTI over 12 month follow-up period with use of placebo tablets to blind study